Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.74 |
| ▸ | CA12 | O43570 | 4/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | MAOA | P21397 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.58 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.58 |
| ▸ | SORD | Q00796 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787335 | 0.85 | MAP1LC3B (1.00) | MAP1LC3BCA12AKR1B1CA9MAOA | |
| SCHEMBL30231625 | 0.82 | MAP1LC3B (0.74) | MAP1LC3BCA12AKR1B1CA9MAOA | |
| SCHEMBL29115369 | 0.77 | MAP1LC3B (0.74) | MAP1LC3BCA12AKR1B1CA9MAOA | |
| SCHEMBL30677928 | 0.77 | MAP1LC3B (0.74) | MAP1LC3BCA12AKR1B1CA9MAOA | |
| SCHEMBL28422580 | 0.77 | ABCB1 (0.74) | CA12AKR1B1CA9MAOAMAOB | |
| SCHEMBL21630173 | 0.75 | ALDH1A1 (0.68) | MAP1LC3BALDH1A1MAPK1ALOX15TSHR | |
| SCHEMBL30231429 | 0.74 | MAP1LC3B (0.55) | MAP1LC3BCA12CA9ALDH1A1MAPK1 | |
| SCHEMBL8580581 | 0.74 | MAP1LC3B (0.80) | MAP1LC3BCA12AKR1B1CA9MAOA | |
| SCHEMBL2987658 | 0.74 | CA9 (1.00) | MAP1LC3BCA12AKR1B1CA9MAOA | |
| SCHEMBL29736952 | 0.74 | CA9 (1.00) | MAP1LC3BCA12AKR1B1CA9MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703735-B2 | 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2020-07-07 | — | — | US | disclosed |
| US-20200031794-A1 | 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-01-30 | — | — | US | disclosed |
| EP-3598972-A1 | 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | Lead Discovery Center GmbH (DE) | 2020-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031794-A1 | 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | POLRMT, COX4I1, UQCRC2 | MAP1LC3B 1339/4885CA12 4725/4885AKR1B1 1658/4885 |
| US-10703735-B2 | 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | POLRMT, COX4I1, UQCRC2 | MAP1LC3B 1339/4885CA12 4725/4885AKR1B1 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.